Eczema: newer targeted drugs went with fewer hospital and ER visits
☕ Includes a question for the family ↓
EczemaPart of a story we are following · 3 articles · See every update
If eczema has ever sent you or someone you love to the ER, here is news worth knowing. Adults who started the newer targeted drugs for eczema ended up in the hospital and the emergency room less often.
The drugs are the ones you may have seen advertised, almost always an injection called dupilumab. They are expensive, and that is true. But the study shows what you get for the money: fewer of the worst days.
How the study worked
Researchers looked at insurance claims from about 158,000 US adults with eczema (atopic dermatitis) who had commercial health insurance. The claims ran from 2012 through 2023. About 9,320 of them, roughly 6%, got a targeted drug, and 99% of those got dupilumab. The team compared how things changed over time for people who got the drugs and for people who did not. The study was published in November 2026 in the Journal of Managed Care and Specialty Pharmacy. It tracks insurance records, so it shows a link and not proof of cause.
What they found
The study covered exactly 157,966 adults. People who started a targeted drug were less likely to be hospitalized in a given year. The drop was about 2 percentage points, or exactly 1.6 percentage points in the study’s numbers. They were also less likely to visit the ER, down about 2 points, or exactly 1.7 percentage points.
So the drugs went with fewer of the scary, disruptive days that eczema can bring.
Now the money. Total health care spending went up by $24,901 a year. All of that came from the drugs themselves, which added $26,061. Spending on hospital stays and on outpatient care went down.
Here is the part that matters for your own wallet. Patients’ own out-of-pocket spending rose by only $95 a year. Most of the price was carried by the insurance plans.
What are targeted drugs?
Most eczema care starts with creams and moisturizers. Targeted drugs work differently. They block specific signals your immune system sends that keep skin inflamed and itchy. Dupilumab is given as an injection. Others, called JAK inhibitors, come as pills.
What you can do today
Give your skin a boost that helps with any eczema treatment. After your next shower, pat dry and put on a fragrance-free moisturizer within a few minutes, while your skin is still slightly damp. If your eczema keeps flaring despite creams, ask your dermatologist whether a targeted drug is a fit for you.
Talk about it at home
Some people have a skin condition called eczema that makes them very itchy. Newer medicines calm the part of the body that causes the itch and swelling. In this study, people taking them needed the hospital and the ER less often.
Question for the table
How would you test whether a medicine really works, and not just that people who take it happen to be different?
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Questions and answers
- What are targeted drugs for eczema?
- They are medicines that block specific immune signals behind skin inflammation. Dupilumab is an injection, and JAK inhibitors come as pills.
- Did they reduce hospital and ER visits?
- Yes. People who used them had a 1.6 percentage point lower chance of hospitalization and a 1.7 point lower chance of an ER visit.
- How much did patients pay out of pocket?
- Out-of-pocket spending rose by $95 a year. Most of the drug cost was covered by insurance.
- Who was in the study?
- Adults with eczema and commercial health insurance in the US, with claims from 2012 through 2023.
